A detailed history of Pdt Partners, LLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 16,227 shares of RLMD stock, worth $48,681. This represents 0.01% of its overall portfolio holdings.

Number of Shares
16,227
Previous 14,920 8.76%
Holding current value
$48,681
Previous $61,000 22.95%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$3.1 - $6.8 $4,051 - $8,887
1,307 Added 8.76%
16,227 $75,000
Q3 2023

Nov 14, 2023

SELL
$2.48 - $3.79 $41,716 - $63,751
-16,821 Reduced 52.99%
14,920 $44,000
Q2 2023

Aug 14, 2023

SELL
$2.22 - $3.54 $83,518 - $133,178
-37,621 Reduced 54.24%
31,741 $78,000
Q1 2023

May 15, 2023

BUY
$2.24 - $4.76 $155,370 - $330,163
69,362 New
69,362 $156,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $85.8M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.